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Evidence is given that phenothiazines depress hepatic peroxisomal fatty acid oxidation in vivo. After oral 
administration to rats thioridazine and chlorpromazine inhibit pcroxisomal p-oxidation, evaluated by Hz02 
production, during 2 weeks. In mice, this effect could not be demonstrated. However, in both species 
VLCFA are increased after short and long term drug administration. Electron microscopy reveals the pres- 
ence of membranous tructures in liver cytoplasm or lysosomes. The inhibition by thioridazine ofperoxiso- 
ma1 B-oxidation does not lead to hepatic peroxisome proliferation. The activities of enzymes related to fatty 
acid breakdown are not increased and liver peroxisomes are microscopically normal. 
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1. INTRODUCTION 
The question raised by the existence of a ,8- 
oxidation system in mammalian liver peroxisomes 
[l] is the partitioning of fatty acids between perox- 
isomal and mitochondrial &oxidations. An im- 
pairment of the former system resulting in the 
accumulation of VLCFA in body fluids and tissues 
exists in patients with peroxisomal diseases [2]. 
Although phenothiazines were demonstrated in ro- 
dent liver to inhibit peroxisomal &oxidation [3,4], 
no animal model for the chronic depression of this 
route has been studied. 
The aim of the present work is to investigate 
whether thioridazine and chlorpromazine, two 
phenothiazines, inhibit peroxisomal &oxidation in 
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normal rats and mice when they are administered 
chronically through the diet. Changes in the perox- 
isomal fatty acid breakdown are evaluated through 
fluctuations of the Hz02 produced by fatty acyl- 
CoA oxidase which catalyzes the first step of this 
pathway. Proliferation of peroxisomes, perox- 
isomal B-oxidizing capacity and accumulation of 
VLCFA are also studied. 
2. MATERIALS AND METHODS 
Adult male Wistar rats (200-300 g) and NMRI 
mice (25-30 g) were fed ad libitum on a standard 
laboratory animal meal (AOCUAR, Epinay, 
France). Treated animals were fed on a diet con- 
taining thioridazine doses ranging from 0.1 to 
0.5% (w/w) and 0.1% (w/w) chlorpromazine. In 
some experiments &oxidation was stimulated for 2 
days by feeding margarine only. 
Thioridazine-hydrochloride was a gift from San- 
doz Pharmaceuticals; chlorpromazine was obtain- 
ed from Serva. 
Peroxisomal &oxidation was evaluated by 
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measuring RCA after inhibition of the catalase- 
Hz02 complex with aminotriazole [S]. 
Aminotriazole (1 g/kg in 0.9% NaCl) and 
methanol (3.5 mmol/kg in rats and 3.2 mmol/kg 
in mice) were administered simultaneously by in- 
traperitoneal injection. Rats were killed by 
decapitation 2 h after administration of 
aminotriazole-methanol, mice after 1 h. Catalase 
activity was assayed in total liver homogenate by 
the titanium oxysulfate method [6]. A lower RCA 
reflects a higher Hz02 production, i.e. higher ac- 
tivity of peroxisomal &oxidation. 
Carnitine acetyltransferases [7], lauroyl-CoA 
and glycolate oxidases [8], D-amino acid oxidase 
[9] and cytochrome P-450 [lO,l l] were assayed by 
established procedures. One unit of enzyme activi- 
ty is the amount of enzyme that catalyzes the con- 
version of 1 pmol of substrate/min. 
Each experimental group consisted of at least 4 
animals. Results are expressed as the mean f SE. 
For statistical analysis the Mann-Whitney test was 
used [13]. 
VLCFA were analyzed in plasma. Their extrac- 
tion was performed as in [ 121 after addition of 2 pg 
heptacosanoic acid as internal standard and before 
transmethylation with 2 M HCl in methanol at 
75’C for 16 h. The gas chromatographic iden- 
tification of the methyl esters was made by com- 
parison of their retention time with reference 
retention times. 
Liver slices of 0.5 mm thickness were fixed at 
room temperature in 4% formol-calcium buffered 
with cacodylate for 24 h. Cryostat sections were 
stained for catalase which visualizes the perox- 
isomes [14]; for electron microscopy they were 
postosmicated and embedded in Epon. 
3. RESULTS 
3.1. Phenothiazines and weight gain 
At a dose of 0.1% thioridazine, weight gain in 
rats is diminished as compared to matched con- 
trols. At doses of 0.25% and 0.5% rats seem to 
lose weight. However, after a short period of 
weight loss, rats receiving a 0.25% thioridazine 
diet are back to their initial weight after about 3 
weeks. From then on, the weight gained curve 
parallels the control curve with a constant dif- 
ference of about 100 g. 
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Table 1 
Influence of a thioridazine diet on peroxisomal ,& 
oxidation in rat liver 
Conditions RCA Total catalase 
(u&g of liver) (Us/g of liver) 
Control diet 43+ la 85+ 5 
0.1% T diet, 1 week SO* 6b - 
0.25% T diet, 1 week 59* 8c - 
0.5% T diet, 1 week 62+ 3d - 
0.25% T diet, 2 weeks 512 5e 111 + 35 (NS) 
0.25% T diet, 3 weeks 41* 7f - 
0.25% T diet, 8 weeks 29 & 3 g 86 f 8 (NS) 
2 days of fat diet 35* 2h 96 + 1 (NS) 
3 weeks 0.25% T + 
2 days of 0.25% 
T fat diet 27 f 1Oi 71* 7(NS) 
3 weeks 0.25% T + 
2 days 0.5% T 55 f 12j 95 f 2 (NS) 
P < 0.01: a vs d, g; P < 0.05: a vs c, e, h; NS: a vs b, 
f, j and h vs i 
In rats (table l), peroxisomal fatty acid 
breakdown is inhibited in animals receiving 
thioridazine at doses larger than 0.1% after 1 
week. Good inhibition is obtained using a 0.25% 
3.2. Phenothiazines and peroxisomal fatty acid 
oxidation 
Table 2 
Influence of a 0.1% chlorpromazine diet on peroxisomal 
&oxidation in rat and mouse liver 
Conditions RCA 
(U&g of liver) 
Rats 
control 
CPZ 1 week 
CPZ 8 weeks 
Mice 
control 
CPZ 1 week 
CPZ 8 weeks 
43 + 1 
60 f 9 
(p < 0.01) 
48 + 5 
(NS) 
41 f 4 
47 f 6 
(NS) 
41 * 4 
(NS) 
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Table 3 
Influence of thioridazine and chlorpromazine on VLCFA concentration (ng/ml) in 
plasma from rats and mice 
Conditions Rat Mouse 
C26 : C22 C24 : C22 C26 :C22 C24 :C22 
Control 0.323 + 0.013 2.413 + 0.027a 0.069 f 0.024 0.571 + 0.084 
2 weeks T 0.196 +_ 0.010 2.975 f 0.066b - - 
8 weeks T 0.298 f 0.039 3.248 * 0.191~ - - 
1 week CPZ 0.257 + 0.110 2.861 f O.llOd 0.131 0.719 
6 weeks CPZ 0.304 & 0.019 2.872 + 0.057e 0.160 0.834 
P < 0.05: a vs b, c; P < 0.01: a vs d, e. Values for CPZ-treated mice were measured 
on pooled samples from 4 animals 
thioridazine diet. At thioridazine doses higher than 
0.25070, toxic effects of the drug become apparent 
(sleepiness, low food intake, diarrhea). A 0.25% 
thioridazine diet was chosen for further ex- 
periments. With this diet the inhibitory effect 
disappears after 2 weeks. After 8 weeks we even 
observe a significantly increased Hz02 production. 
Inhibition by the drug cannot be restored when ,& 
oxidation is first stimulated by fat feeding or by in- 
creased drug doses. Total liver catalase activity is 
not changed by a 0.25% thioridazine diet. 
Cytochrome P-450 is not changed after 3 weeks 
of a 0.25% thioridazine diet (45.8 +- 6.4 nmol/g of 
liver in thioridazine-treated rats and 46.9 + 
Fig. 1. Electron micrographs of membranous lamellae in liver cells. (A) Rigid lamellae in Kupffer cell lysosomes of rats 
treated with thioridazine for 2 weeks; chlorpromazine induces identical structures. They are presented as 3 parallel ines 
limiting 2 electronlucent spaces. The distance between the outer lines is about 110 A. (B) Lamellae with irregular spacing 
in parenchymal cells of chlorpromazine-treated rats (8 weeks). They are reminiscent of lamellae seen in human 
peroxisomal diseases. (C) Irregularly spaced lamellae in liver parenchymal cells of a patient with pseudo-neonatal 
adrenoleukodystrophy [20]. 
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6.3 nmol/g of liver in control rats). Table 4 
A 0.1% chlorpromazine diet inhibits perox- 
isomal &oxidation in rat liver after 1 week. After 
long term administration of chlorpromazine (8 
weeks) this inhibitory effect has disappeared (table 
2). 
Activities of several peroxisomal enzymes, carnitine 
acyltransferases and butyryl-CoA dehydrogenase in 
livers from thioridazine-treated (8 weeks) and untreated 
rats 
The plasma C26 : C22 ratio is diminished after 1 
and 2 weeks of chlorpromazine or thioridazine 
diet; after 8 weeks it is back to normal. The 
C24 : C22 ratio is increased both after 1, 2 and 8 
weeks of drug administration (table 3). 
Electron microscopy of liver reveals the presence 
of membranous lamellae in lysosomes of non- 
parenchymal cells (thioridazine and chlor- 
promazine) as well as in the cytoplasm of the 
parenchyma at the rim of fat droplets (chlor- 
promazine) (fig.1). In analogy with the human 
peroxisomal diseases, such material is believed to 
represent VLCFA deposition [ 151. These lamellae 
are not seen in livers from untreated animals. 
Enzymes 
D-Proline oxidase 
Glycolate oxidase 
Lauroyl-CoA oxidase 
Cyanide insensitive 
+T Untreated 
2344 f 568 2096 f 312 
854 f 150 1014 f 58 
1138 * 52 1048 * 64 
lauroyl-CoA oxidation 1457 f 97 1356 f 118 
Carnitine acetyltransferase 642 + 150 632 f 96 
Carnitine octanoyl- 
transferase 
Carnitine palmitoyl- 
1515 Z!Z 302 1412 f 156 
transferase 1252 + 110 1304 f 126 
Butyryl-CoA dehydrogenase 1512 + 56 1687 f 138 
In mice the inhibitory effect of chlorpromazine 
cannot be shown after 1 and 6 weeks of drug diet. 
Nevertheless, increased plasmatic C26 : C22 and 
C24 : C22 ratios were present after 1 and 6 weeks of 
chlorpromazine diet (table 3). 
Activities are expressed as mU/g of tissue. Values are 
not significantly different in treated and untreated rats 
3.3. Phenothiazines and peroxisomal proliferation 
After 2 (not shown) and 8 weeks of a 0.25% 
thioridazine diet enzymes related to peroxisomal ,& 
oxidation are not significantly induced in rat liver 
(table 4). 
Liver sections do not show light microscopic 
changes of peroxisomal number after short and 
long term thioridazine or chlorpromazine diets in 
rats and mice. 
4. DISCUSSION 
Our results demonstrate that the short term ad- 
ministration of phenothiazines to rodents can 
depress liver peroxisomal &oxidation. Never- 
theless it is clear that this effect, assayed by perox- 
isomal Hz02 production, is only transitory (rats) 
or not detectable (mice). The long term administra- 
tion of phenothiazines does not depress overall 
peroxisomal fatty acid oxidation and can even 
stimulate it. How can we explain that, in the latter 
conditions, VLCFA which are specifically oxidized 
by peroxisomes, accumulate in tissues (trilamellar 
structures) and in body fluids (increased plasmatic 
VLCFA) from animals given phenothiazines? One 
must absolutely distinguish the flux of fatty acids 
through peroxisomal P-oxidation (which repre- 
sents the sum of the peroxisomal acyl-CoA 
oxidizing reactions expressed per time unit) from 
the activity of this pathway on the various classes 
of fatty acids. The former is estimated by the 
measurement of RCA which mainly depends on 
the Hz02 produced by the fatty acyl-CoA oxidase 
and is not (in mice) or slightly (in rats) inhibited by 
phenothiazines in vivo. The second could be 
modified by the drugs according to scheme 1. The 
bulk of physiological fatty acids are LCFA and 
evidence has previously been given that the entry 
of these substrates into peroxisomes can be 
carnitine-dependent [16]. LCFA can also enter 
these organelles in the form of acyl-CoA esters 
[ 171. The inhibition by phenothiazines of COT [ 161 
directly impairs carnitine-dependent entry of 
LCFA into peroxisomes. We suggest that the latter 
change, even if it does not or poorly inhibit the 
flux of fatty acids through peroxisomal ,&- 
oxidation, could dramatically affect the propor- 
tions of the various classes of fatty acids which are 
oxidized by peroxisomes especially VLCFA which 
must normally enter peroxisomes in the form of 
acyl-CoA esters since they are not substrates for 
carnitine acyltransferase. Abnormal competition 
24 
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? I + Phenothiazines 
VLCFA-CoA 
VLCFA-CoA 
LCFA-CoA LCFA-CoA 
p-ox 
between long chain acyl-CoA and very long chain 
acyl-CoA for the peroxisomal membranal 
transport of acyl-CoA moieties could take place 
under the administration of phenothiazines. 
We have as yet no explanation why in rats RCA 
is temporarily increased and not in mice. We 
remarked that chlorpromazine is more toxic to 
mice than to rats. None of the experimental rats 
died during a 0.1% chlorpromazine diet, while 
mortality was high in mice (13 out of 20 mice). 
Perhaps intoxication causes diminished food in- 
take. We demonstrated earlier that fasting causes 
an increased flux of fatty acids through the perox- 
isomal oxidase [5]; this might mask a partial in- 
hibition. 
Recently Vamecq et al. [18] have shown the 
presence of trilamellar structures in the liver of 
mice treated with a 0.1% chlorpromazine diet for 
6 weeks. In rats, we find membranous inclusions 
which are not completely identical. After 8 weeks 
of a chlorpromazine diet they are very similar to 
those in livers from 2 patients with peroxisomal 
Scheme 1. Hypothetic influence of the phenothiazine 
dependent inhibition of carnitine octanoyltransferase 
(COT) on the peroxisomal handling of very long chain 
acyl-CoA esters (VLCFA-CoA). (A) Evidence has 
previously been given that LCFA can enter peroxisomes 
in the form of acyl-CoA (pathway 1) or acylcarnitine 
(pathway 2) esters which are abbreviated LCFA-CoA 
and LCFA-Cn, respectively. One of the functions of 
COT is to allow peroxisomal oxidation of LCFA-Cn by 
conversion to the corresponding CoA derivatives. In this 
representation it is assumed that the transmembranal 
transport mechanisms for the acyl-CoA esters are 
different from those involved in the peroxisomal entry 
of the acylcarnitine moieties. P.M., peroxisomal 
membrane; P-OX., peroxisomal P-oxidation system. (B) 
The inhibition of COT must prevent or inhibit the 
acylcarnitine-mediated mode of entry of LCFA into the 
peroxisome. In these conditions, only the acyl-CoA- 
mediated mode of entry for LCFA remains possible. 
This is expected to interfere with the handling by 
peroxisomes of VLCFA possibly at the level of entry of 
VLCFA-CoA in these organelles. Phenothiazines can act 
by shifting the peroxisomal oxidation of fatty acids from 
situation A to situation B. This change is associated 
(isolated hepatocytes [3] and short term influence of 
phenothiazines in rats) or not (short term influence of 
phenothiazines in mice and long term influence in rats 
and mice) with a decreased flux of fatty acids through 
the peroxisomal @-oxidation assayed by Hz02 
production. Other comments are given in the text. 
diseases: a patient with the pseudo-Zellweger syn- 
drome [19] and a patient in whom a diagnosis of 
pseudo-neonatal adrenoleukodystrophy was made 
[20] (fig. 1). They are reminiscent of the inclusions 
in adrenal cortex cells and brain macrophages 
found in human peroxisomal diseases [21-241. 
They differ however from the trilamellar inclu- 
sions seen in livers from phytanic oxidase deficien- 
cy or genuine CHRS patients [14]. 
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